Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection

Detalles Bibliográficos
Autores principales: Shopen, Noah, Dekel, Michal, Mizrahi, Michal, Zandberg, Efrat, Talmud, Daniel, Cohen, Neta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919793/
https://www.ncbi.nlm.nih.gov/pubmed/35300887
http://dx.doi.org/10.1016/j.ejim.2022.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919793/
https://www.ncbi.nlm.nih.gov/pubmed/35300887
http://dx.doi.org/10.1016/j.ejim.2022.03.001

Ejemplares similares